William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
William Blair Reiterates Outperform Rating on ServiceTitan (TTAN): 'we view valuation as attractive'
View Older Stories
-
William Blair Reiterates Market Perform Rating on El Pollo Loco (LOCO) following earnings report
-
William Blair Downgrades PagerDuty (PD) to Market Perform
-
William Blair Reiterates Outperform Rating on VSE Corporation (VSEC): "We view today’s 7% stock drawdown as a buying opportunity"
-
Form N-CEN WILLIAM BLAIR FUNDS For: Dec 31
-
Xenon Pharmaceuticals closes $747.5 million public offering
-
Dianthus Therapeutics completes $719 million public offering
-
William Blair Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "entering 2026 with increasing momentum"
-
William Blair Reiterates Market Perform Rating on UiPath Inc. (PATH): "incrementally encouraged"
-
William Blair Reiterates Outperform Rating on Aveanna Healthcare Holdings Inc (AVAH) following acquisition announcement
-
Oxford Lane Capital announces preferred stock offering
-
William Blair: 'We like CRCL for long-term investors'
-
William Blair Reiterates Outperform Rating on AppLovin Corp (APP) following meeting with management
-
William Blair Reiterates Market Perform Rating on Sprinklr Inc (CXM): "a lot to prove on the execution front"
-
William Blair: 'increasing likelihood that Oracle sees significant earnings growth acceleration over the coming years'
-
Dianthus Therapeutics prices $625 million public stock offering
-
Xenon Pharmaceuticals prices $650 million stock offering at $57 per share
-
William Blair Reiterates Outperform Rating on Veeva Systems (VEEV) amid Ostro acquisition
-
William Blair Reiterates Outperform Rating on Tenax Therapeutics (TENX): "continue to believe positive top-line results from LEVEL have the potential to drive multifold upside"
-
Medline completes $3.5 billion secondary stock offering
-
William Blair Reiterates Outperform Rating on Exagen (XGN) following Q4 results
-
William Blair Reiterates Outperform Rating on LENZ Therapeutics Inc (LENZ): "continue to believe VIZZ holds blockbuster potential"
-
William Blair Reiterates Outperform Rating on Standex International (SXI) following meetings with management
-
William Blair Starts BridgeBio Pharma (BBIO) at Outperform
-
MiniMed closes IPO raising $538 million at $20 per share
-
William Blair Reiterates Outperform Rating on Nayax (NYAX) following earnings
-
William Blair Reiterates Outperform Rating on StoneX Group Inc. (SNEX): "current price looks highly attractive"
-
Dianthus Therapeutics announces $400 million public stock offering
-
Xenon Pharmaceuticals announces $500 million public offering
-
William Blair Reiterates Outperform Rating on Kalaris (KLRS): "we see blockbuster potential for TH103 in nAMD"
-
William Blair Reiterates Outperform Rating on Microsoft (MSFT) following product announcements
-
William Blair Reiterates Market Perform Rating on ULTA Beauty (ULTA) ahead of earnings
-
William Blair: 'We expect Microsoft to continue expanding its enterprise wallet share'
-
William Blair Reiterates Outperform Rating on Crawford & Company (CRD-B): "Significant upside is possible"
-
William Blair Reiterates Outperform Rating on Abbvie (ABBV): "competitive across the amylin class"
-
William Blair Downgrades TalkSpace (TALK) to Market Perform
-
William Blair Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE): "we see further room for upside"
-
William Blair Reiterates Outperform Rating on Korn/Ferry (KFY) following Q3 results
-
William Blair Reiterates Outperform Rating on Dianthus Therapeutics (DNTH): "remain bullish here"
-
William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY) following Q4 results
-
William Blair: '$15 move in oil can cause FCF yield to more than double'
-
Korro Bio raises $85 million in oversubscribed private placement
-
William Blair Starts Jade Biosciences (JBIO) at Outperform
-
William Blair Reiterates Outperform Rating on Amprius Technologies (AMPX): "best-positioned arms dealer to supply this burgeoning industry"
-
William Blair Reiterates Outperform Rating on Stitch Fix, Inc. (SFIX): "Pullback Creates Compelling Entry Point"
-
William Blair Reiterates Outperform Rating on Crescent Energy (CRGY) following convertible notes offering announcement
-
William Blair Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Market Perform, Removed from Analyst Conviction List
-
William Blair: 'we believe Marvell is well positioned to grab its fair share of the AI infrastructure wallet'
-
Ingram Micro prices secondary offering at $22.25 per share
-
MiniMed prices IPO at $20 per share, raising $560 million
-
Form 497K WILLIAM BLAIR FUNDS

